1 / 13

From Balance sheet to economic analysis

This project, led by Dott.ssa Notaro and Dott.ssa Stefanoni, focuses on the analysis of balance sheets and income statements, alongside financial and economic cost-benefit analyses (CBA) related to producing Antiretroviral (ARV) drugs in Sub-Saharan Africa. The main objective is to increase the availability of affordable ARV therapy, enhance life expectancy, and alleviate the economic burden of HIV/AIDS. Stakeholders include the Sigma Tau private sector and the Sudanese government, with project activities aimed at establishing a local plant for ARV drug production and researching an AIDS vaccine.

noam
Télécharger la présentation

From Balance sheet to economic analysis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. From Balance sheet to economic analysis Dott.ssa Notaro Dott.ssa Stefanoni

  2. What we are going to study • Balance sheet analysis and Income Statement analysis • Financial CBA • Economic CBA

  3. Producing ARV in Sub-Saharan Africa Project Objective • The project aims to increase the offer of Antiretroviral drugs in Sub-Saharan Africa by reducing the price of Antiretroviral therapy • Project stakeholders • Private sector Sigma Tau • Government Sudan Government

  4. Project activities • Build up a plant to produce and can Antiretroviral (ARV) drugs in Sudan • Finance the research on AIDS vaccine for both adults and children

  5. Expected impact • Increase life expectancy of infected people • Improve the quality oflife by transforming a mortal disease in a manageable chronic illness • Alleviate the economic impact of HIV/AIDS in Sub-Saharan Africa

  6. Analysis structure Balance Sheet and Income statement analysis Financial CBA Sigma Tau Sudan Government Economic CBA

  7. Social and Economic Framework • In the world there are 40 millions people living with HIV • Africa accounts for 10% of the total world's population but the 83% of deaths caused by AIDS occurs in Africa • Sub-Saharan Africa accounts for 28.1 people living with HIV/ADS. • WHO’s members have reached an agreement to allow LDCs countries to make use of compulsory licenses to import or produce in loco low cost generic drugs

  8. Market Analysis: Demand • Africa didn’t experiment any reduction in the rate of prevalence of HIV/AIDS • Between 1990 and 2000 the spread of epidemic has increased in the region • At present in Africa the 99% of people living with HIV don’t have access to ARV Therapy (ART)

  9. Potential demand

  10. Market Analysis: Supply • ART has become more affordable through international competition between producers of generic drug. (From 10.000 US$ per year to 290US$ per year) • So far there are not factories that produce ART in Sub-Saharan Africa

  11. Expenditures • Investment costs • Engineering costs • Personnel costs • Operating costs • Row materials • Personnel • Distribution

  12. CBA and Balance sheet Costs

  13. Benefits Benefits

More Related